| __timestamp | Vericel Corporation | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13774000 | 7461000 |
| Thursday, January 1, 2015 | 22479000 | 11960000 |
| Friday, January 1, 2016 | 27388000 | 13108000 |
| Sunday, January 1, 2017 | 35610000 | 17501000 |
| Monday, January 1, 2018 | 49007000 | 22472000 |
| Tuesday, January 1, 2019 | 61139000 | 24286000 |
| Wednesday, January 1, 2020 | 68836000 | 29689000 |
| Friday, January 1, 2021 | 97592000 | 38837000 |
| Saturday, January 1, 2022 | 106903000 | 47489000 |
| Sunday, January 1, 2023 | 120998000 | 53379000 |
Unlocking the unknown
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Vericel Corporation and Xencor, Inc. have been navigating this challenge since 2014. Over the past decade, Vericel's SG&A expenses have surged by approximately 780%, reaching a peak in 2023. In contrast, Xencor's expenses have grown by about 615% over the same period.
Vericel's expenses consistently outpaced Xencor's, with a notable spike in 2021, where their SG&A costs were nearly double those of Xencor. This trend suggests Vericel's aggressive investment in administrative functions, possibly to support rapid growth. Meanwhile, Xencor's more conservative approach may reflect a focus on maintaining lean operations. As both companies continue to evolve, their strategies in managing these costs will be pivotal in determining their competitive edge.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Dr. Reddy's Laboratories Limited and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Comparing Innovation Spending: Vericel Corporation and Xencor, Inc.
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.